skip to Main Content
New Jersey Medicinal Marijuana Review Panel recommends adding chronic pain and other conditions
TRENTON, NJ— On Thursday, May 11, the New Jersey Medicinal Marijuana Program Review Panel made initial recommendations to the Health Commissioner to approve chronic pain related to musculoskeletal disorders, migraines, anxiety, chronic fatigue related to ailments such as irritable bowel syndrome, Tourrette syndrome as qualifying conditions for the medical marijuana program.

“We are glad to see that the panel took the testimony of experts and the petitions of New Jerseyans seriously in making their recommendation to add chronic pain to the list of qualifying conditions for medical marijuana,” said Roseanne Scotti, New Jersey State Director of the Drug Policy Alliance. “Many people across the state will be helped by this decision.  And it comes at a particularly important moment. Data shows that states with medical marijuana programs that allow access for individuals with chronic pain have reduced dependence on opioids. As New Jersey continues dealing with problematic opioid use in our state, expanding the medical marijuana program to include chronic pain is a real solution that can be immediately implemented.”

The panel’s initial recommendations are now open for a 60-day comment period and will be addressed at a public hearing before being finalized and sent to the Health Commissioner who will make the final determination on petitions to add new conditions to the state’s medical marijuana program.

The New Jersey Policy Office of the Drug Policy Alliance successfully led a campaign in partnership with medical and professional organizations as well as patient advocates to pass the New Jersey Compassionate Use Medical Marijuana Act in 2010. The coalition has been advocating for improvements to the state’s program since implementation. The Drug Policy Alliance submitted a petition in support of adding chronic pain, collected letters of support from clinicians and New Jerseyans suffering from the condition, and organized expert testimony before the Review Panel at their February meeting.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

New Hampshire’s medical marijuana industry concerned about its future under legalization proposal

New Hampshire’s medical marijuana industry, which has dispensed cannabis to thousands of ailing people, could face an existential threat if it is not protected under a proposal to legalize the…

What you need to know about Minnesota’s marijuana legalization bill

After months of debate in more than two dozen committees, the Legislature has passed a sweeping 321-page bill to legalize marijuana in the state. Legislative negotiators ironed out differences between…

Marijuana linked to mental health risks in young adults, growing evidence shows

Over the last decade of diagnosing countless young patients with new psychotic disorders, one striking result has stuck out for New York City psychiatrist Dr. Ryan Sultan. “Of all the…

SEC Shuts Down WeedGenics For $60 Million Alleged Cannabis Ponzi Scheme

The U.S. Securities and Exchange Commission (SEC) has announced that it has obtained an emergency order to shut down WeedGenics, an alleged Ponzi-like scheme orchestrated by two individuals who managed…

More Categories

Back To Top
×Close search